We are excited to announce that US BioTek will now be offering Monkeypox testing to all of our providers based in the United States. With the launch of this test, we will be providing a faster way for individuals to know their Monkeypox infection status.
“As we have seen in recent years, quantifying our viral statuses as quickly as possible can have huge impacts on our personal and public health,” says Jack Frausing, Chief Executive Officer at US BioTek Laboratories. "At US BioTek, we strive to offer our customers the testing they need to improve the lives of their patients. In the case of Monkeypox, we are doing so by offering test results in less than 24 hours.”
Monkeypox Diagnostic Testing utilizes a lesion swap specimen and uses real-time polymerase chain reaction (RT-PCR) testing to detect Monkeypox, as recommended by the CDC.
The benefits of US BioTek Laboratories Monkeypox Diagnostic Testing include:
- Results are delivered within 24 hours of receiving specimens
- Simple collection method using a skin lesion swab
- Easy to read positive/negative report formats
Monkeypox diagnostic testing is available as of October 13th, 2022, to all practitioners with US BioTek accounts. To sign up for a US BioTek Practitioner Account, visit https://www.usbiotek.com/create-account.
For more information on Monkeypox testing, visit https://www.usbiotek.com/tests/monkeypox.